| Brian Arthur Feagins, MD | |
|
10501 N. Central Expressway, Suite 200, Dallas, TX 75231-2200 | |
| (214) 360-1535 | |
| (214) 360-1534 |
| Full Name | Brian Arthur Feagins |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 37 Years |
| Location | 10501 N. Central Expressway, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649229790 | NPI | - | NPPES |
| 80407X | Other | TX | BCBS |
| P00194243 | Other | TX | MEDICARE RR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | H5440 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Texas Health Presbyterian Hospital Dallas | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urology Clinics Of North Texas, Pllc | 5496736415 | 68 |
News Archive
An extreme body mass index or high waist-to-hip ratio, both measures of body fat, increased risk for mortality among patients with breast cancer, but this association varied by race/ethnicity, according to recently presented data.
Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.
VisiVite, a world leader in ocular nutrition, today announced its upcoming January 2015 release of ProVision, a professional macular health formula designed to be easy for eye doctors to dispense and affordable for their patients to use.
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
› Verified 1 days ago
| Entity Name | Urology Clinics Of North Texas, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971549 PECOS PAC ID: 5496736415 Enrollment ID: O20040526000711 |
News Archive
An extreme body mass index or high waist-to-hip ratio, both measures of body fat, increased risk for mortality among patients with breast cancer, but this association varied by race/ethnicity, according to recently presented data.
Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.
VisiVite, a world leader in ocular nutrition, today announced its upcoming January 2015 release of ProVision, a professional macular health formula designed to be easy for eye doctors to dispense and affordable for their patients to use.
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian Arthur Feagins, MD 3600 Gaston Ave, Ste 1205, Dallas, TX 75246-1800 Ph: (214) 692-8262 | Brian Arthur Feagins, MD 10501 N. Central Expressway, Suite 200, Dallas, TX 75231-2200 Ph: (214) 360-1535 |
News Archive
An extreme body mass index or high waist-to-hip ratio, both measures of body fat, increased risk for mortality among patients with breast cancer, but this association varied by race/ethnicity, according to recently presented data.
Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.
VisiVite, a world leader in ocular nutrition, today announced its upcoming January 2015 release of ProVision, a professional macular health formula designed to be easy for eye doctors to dispense and affordable for their patients to use.
US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer.
› Verified 1 days ago
Dr. Xiaosong Meng, M.D., PH.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5200 Harry Hines Blvd, Dallas, TX 75235 Phone: 214-590-8000 | |
Bruce Jeremy Schlomer, MD Urology Medicare: Medicare Enrolled Practice Location: 2350 N Stemmons Fwy, Suite D-4300, Mc F4.04, Dallas, TX 75207 Phone: 214-456-2444 | |
Dr. Jodi Antonelli, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-5615 Fax: 214-648-8786 | |
Dr. Eric Bryan Smith, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3417 Gaston Ave, Ste 830, Dallas, TX 75246 Phone: 214-826-6235 Fax: 214-828-4633 | |
Gary Evan Lemack, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-8765 | |
Dr. Homa Jackson Porter Ii, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 8230 Walnut Hill Ln, Suite 700, Dallas, TX 75231 Phone: 214-691-1902 Fax: 214-987-1845 | |
Dr. Michelle Leigh Mcdonald, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 6201 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-633-5555 |